Navigation Links
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
Date:12/11/2008

thin 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance of annual physicals for children before the school year.

Seasonal Influenza

The majority of individuals with influenza recover in less than two weeks; however, some may develop life-threatening complications such as pneumonia. In addition, influenza exacerbates the symptoms of chronic health conditions such as diabetes, asthma and congestive heart failure. The most severe disease occurs in infants and young children and adults older than 65 years of age. The CDC reports that 15 to 60 million people in the U.S. contract influenza each year leading to over 200,000 hospitalizations and 36,000 deaths. The Advisory Committee on Immunization Practices ("ACIP"), which has been expanding recommendations for seasonal influenza vaccination for the last several years, currently recommends seasonal influenza vaccination for children 6 months through 18 years of age, pregnant women, adults over 50 years of age, and individuals of any age with chronic health conditions or who are at high risk of influenza disease. Based on the expanding recommendation of vaccination to new age groups, the growing worldwide population to be vaccinated, and the need of an improved influenza vaccine for the elderly, global market projections of seasonal influenza are estimated to increase from $2.8 billion in 2007 to $6.5 billion by 2013.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... ... Properties - ... TRIANGLE PARK, N.C., July 22 CeNeRx BioPharma,Inc., a clinical stage company ... announced,plans to advance its lead candidate Tyrima(TM) into Phase II trials for ...
... and pegylated enzyme produces significantly enhanced survival ... ... DIEGO, July 22 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... today,announced the presentation of positive pre-clinical animal efficacy data,for its ...
Cached Medicine Technology:CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5
(Date:8/3/2015)... ... August 03, 2015 , ... The ... (ICC) announce an agreement to collaborate across a wide range of initiatives ... building code knowledge among architects. , “Our combined membership, consisting of practicing design ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
Breaking Medicine News(10 mins):Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... ARLINGTON, Va., Dec. 2 From more than 1,100 photos ... and peace, the LIFE Foundation has selected six winners in ... flickr.com. The winning photos can be viewed in a video ... . , Contestants submitted one photo and a caption ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , WASHINGTON and REDMOND, Wash., Dec. 2 ... announced the companies will collaborate to give caregivers single-point access ... after patients leave the hospital and to give patients and ... Living is the first post-acute care organization to adopt Microsoft ...
... to life span in males , WEDNESDAY, Dec. 2 (HealthDay ... and other mammals and could help explain why females tend ... researchers found that mice created using two female genomes -- ... than mice created from the normal combination of a male ...
... found drinking five or more per week prior to ... (HealthDay News) -- Women who drink five or more ... increase their risk of developing diabetes during pregnancy, a ... association with other chronic metabolic problems," said study author ...
... , LONDON, Dec. ... of improved therapies to treat lifestyle disorders. In the near ... witness enhanced therapies and novel drugs to treat such conditions ... ) , New analysis from Frost & Sullivan ( http://www.pharma.frost.com ...
Cached Medicine News:Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 2Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 4Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:Sugary Colas Tied to Gestational Diabetes 2Health News:Sugary Colas Tied to Gestational Diabetes 3Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 2Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: